Article Details

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis ...

Retrieved on: 2025-07-27 14:44:48

Tags for this article:

Click the tags to see associated articles and topics

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis .... View article details on hiswai:

Excerpt

ANI Pharmaceuticals releases results for ILUVIEN in treating diabetic macular edema. Advertisement. Data analyst working on business analytics ...

Article found on: www.modernretina.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo